On the public citation graph
Regulating the Innovators: Approval Costs and Innovation in Medical Technologies
0 signed · 59 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1007/978-1-349-15430-2_11openalex-snapshot
The Economic Implications of Learning by Doing
inferredcites →https://doi.org/10.1007/978-94-015-7957-5_17openalex-snapshot
The Judgment Proof Problem
inferredcites →https://doi.org/10.1016/j.econlet.2006.04.009openalex-snapshot
Entry barriers and growth
inferredcites →https://doi.org/10.1016/j.jeconom.2021.03.014openalex-snapshot
Difference-in-differences with variation in treatment timing
inferredcites →https://doi.org/10.1016/j.jhealeco.2021.102549openalex-snapshot
The economics of medical procedure innovation
inferredcites →https://doi.org/10.1016/j.jpubeco.2016.11.010openalex-snapshot
Innovation Under Regulatory Uncertainty: Evidence from Medical Technology
inferredcites →https://doi.org/10.1016/s1574-0102(03)01006-9openalex-snapshot
Agency, Information and Corporate Investment
inferredcites →https://doi.org/10.1016/s2468-2667(18)30213-5openalex-snapshot
Funding and services needed to achieve universal health coverage: applications of global, regional, and national estimates of utilisation of outpatient visits and inpatient admissions from 1990 to 2016, and unit costs from 1995 to 2016
inferredcites →https://doi.org/10.1017/s0003055404041383openalex-snapshot
Protection without Capture: Product Approval by a Politically Responsive, Learning Regulator
inferredcites →https://doi.org/10.1038/s41586-019-0941-9openalex-snapshot
Large teams develop and small teams disrupt science and technology
inferredcites →https://doi.org/10.1086/260107openalex-snapshot
An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments
inferredcites →https://doi.org/10.1086/467515openalex-snapshot
An Economic Analysis of Legal Rulemaking
inferredcites →https://doi.org/10.1086/670271openalex-snapshot
Financial Frictions and the Persistence of History: A Quantitative Exploration
inferredcites →https://doi.org/10.1086/705329openalex-snapshot
Transparency and Negotiated Prices: The Value of Information in Hospital-Supplier Bargaining
inferredcites →https://doi.org/10.1093/qje/qjw040openalex-snapshot
Technological Innovation, Resource Allocation, and Growth*
inferredcites →https://doi.org/10.1093/qje/qjz014openalex-snapshot
The Effect of Minimum Wages on Low-Wage Jobs*
inferredcites →https://doi.org/10.1093/restud/rdae007openalex-snapshot
Revisiting Event-Study Designs: Robust and Efficient Estimation
inferredcites →https://doi.org/10.1093/rfs/hht009openalex-snapshot
Wrongful Discharge Laws and Innovation
inferredcites →https://doi.org/10.1111/j.1430-9134.1997.00377.xopenalex-snapshot
Firm Characteristics and the Speed of FDA Approval
inferredcites →https://doi.org/10.1111/j.1748-5991.2010.01091.xopenalex-snapshot
Approval regulation and endogenous consumer confidence: Theory and analogies to licensing, safety, and financial regulation
inferredcites →https://doi.org/10.1115/1.4006781openalex-snapshot
Medical Device Innovators and the 510(k) Regulatory Pathway: Implications of a Survey-Based Assessment of Industry Experience
inferredcites →https://doi.org/10.1162/0033553041382166openalex-snapshot
Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry
inferredcites →https://doi.org/10.1162/0033553041502144openalex-snapshot
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
inferredcites →https://doi.org/10.1162/0033553053970214openalex-snapshot
Competition and Innovation: An Inverted-U Relationship*
inferredcites →https://doi.org/10.1162/rest.91.1.20openalex-snapshot
The Effects of Entry on Incumbent Innovation and Productivity
inferredcites →https://doi.org/10.1162/rest_a_00049openalex-snapshot
Inference with “Difference in Differences” with a Small Number of Policy Changes
inferredcites →https://doi.org/10.1257/aer.104.10.3186openalex-snapshot
Productivity Losses from Financial Frictions: Can Self-Financing Undo Capital Misallocation?
inferredcites →https://doi.org/10.1257/aer.20131176openalex-snapshot
Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials
inferredcites →https://doi.org/10.1257/aer.20160346openalex-snapshot
Drilling Like There’s No Tomorrow: Bankruptcy, Insurance, and Environmental Risk
inferredcites →https://doi.org/10.1257/aer.20180946openalex-snapshot
Regulating Innovation with Uncertain Quality: Information, Risk, and Access in Medical Devices
inferredcites →https://doi.org/10.1257/aer.20210107openalex-snapshot
The Impact of Regulation on Innovation
inferredcites →https://doi.org/10.1257/app.20150310openalex-snapshot
The Causal Effect of Competition on Prices and Quality: Evidence from a Field Experiment
inferredcites →https://doi.org/10.13063/egems.1253openalex-snapshot
A Primer to the Structure, Content and Linkage of the FDA’s Manufacturer and User Facility Device Experience (MAUDE) Files
inferredcites →https://doi.org/10.1377/hlthaff.23.1.52openalex-snapshot
The Political Economy Of FDA Drug Review: Processing, Politics, And Lessons For Policy
inferredcites →https://doi.org/10.1377/hlthaff.25.1.57openalex-snapshot
The Pricing Of U.S. Hospital Services: Chaos Behind A Veil Of Secrecy
inferredcites →https://doi.org/10.2139/ssrn.1306944openalex-snapshot
Competition and Innovation: An Inverted U Relationship
inferredcites →https://doi.org/10.2139/ssrn.1570663openalex-snapshot
Wrongful Discharge Laws and Innovation
inferredcites →https://doi.org/10.2139/ssrn.2193068openalex-snapshot
Technological Innovation, Resource Allocation and Growth
inferredcites →https://doi.org/10.2139/ssrn.2420627openalex-snapshot
The Causal Effect of Competition on Prices and Quality: Evidence from a Field Experiment
inferredcites →https://doi.org/10.2139/ssrn.3522328openalex-snapshot
Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents
inferredcites →https://doi.org/10.3386/w12027openalex-snapshot
The Effects of Entry on Incumbent Innovation and Productivity
inferredcites →https://doi.org/10.3386/w15603openalex-snapshot
The Effects of Product Liability Exemption in the Presence of the FDA
inferredcites →https://doi.org/10.3386/w16683openalex-snapshot
The Diffusion of Scientific Knowledge Across Time and Space: Evidence from Professional Transitions for the Superstars of Medicine
inferredcites →https://doi.org/10.3386/w22039openalex-snapshot
Transparency and Negotiated Prices: The Value of Information in Hospital-Supplier Bargaining
inferredcites →https://doi.org/10.3386/w25018openalex-snapshot
Difference-in-Differences with Variation in Treatment Timing
inferredcites →https://doi.org/10.3386/w25068openalex-snapshot
When does Product Liability Risk Chill Innovation? Evidence from Medical Implants
inferredcites →https://doi.org/10.3386/w26679openalex-snapshot
Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents
inferredcites →https://doi.org/10.4324/9781315197296-16openalex-snapshot
Ex Post Liability for Harm vs. Ex Ante Safety Regulation: Substitutes or Complements?
inferredcites →https://doi.org/10.47004/wp.cem.2022.1122openalex-snapshot
Revisiting event study designs: robust and efficient estimation
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4758138openalex-extracted
Product Liability Litigation and Innovation: Evidence from Medical Devices
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2023.102855openalex-snapshot
Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D
inferred← citeshttps://doi.org/10.1080/10438599.2025.2511865openalex-snapshot
Vaccine production and innovation: insights from tort reform and Medicare expansion
inferred← citeshttps://doi.org/10.1136/bmjsit-2023-000186openalex-snapshot
Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
inferred← citeshttps://doi.org/10.2139/ssrn.3731669openalex-snapshot
Regulating Ethical Experimentation: Impacts of the Breakthrough Therapy Designation on Drug R&D
inferred← citeshttps://doi.org/10.2139/ssrn.4612555openalex-snapshot
Vaccine Production and Innovation: Insights from Tort Reform and Medicare Expansion
inferred← citeshttps://doi.org/10.2139/ssrn.6156527openalex-snapshot
Wireless Communications Equipment Markets: Evolution, Classification, and Measurement
inferred← citeshttps://doi.org/10.3386/w32215openalex-snapshot
Product Liability Litigation and Innovation: Evidence from Medical Devices
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.